Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Annovis Bio Phase 3 AD Trial Fully Enrolled
Business clinical trial update

Annovis Bio Phase 3 AD Trial Fully Enrolled

Analysis based on 6 articles · First reported Aug 14, 2026 · Last updated Aug 14, 2026

Sentiment
40
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of full enrollment in the pivotal Phase 3 AD trial is a positive catalyst for Annovis Bio, potentially boosting investor confidence and the stock price. However, the company's increased R&D expenses and net loss may temper short-term gains, and the market will closely watch the upcoming data readouts in 2027.

Biotechnology Pharmaceuticals
Event Summary

Annovis Bio, Inc. (NYSE: ANVS) announced on August 14, 2026, that its pivotal Phase 3 Alzheimer's disease (AD) trial has reached full enrollment with 850 patients, exceeding the original target of 760. The trial evaluates buntanetap, an investigational oral therapy for neurodegenerative diseases. The company also reported that its Parkinson's disease (PD) open-label extension (OLE) study has enrolled 266 patients toward a goal of 500, with full enrollment projected in Q4 2026. Annovis plans to initiate an AD OLE study in October 2026 and expects topline symptomatic data from the Phase 3 trial in Q1 2027. The company also promoted Cheng Fang, Ph.D., to Chief Scientific Officer. Financially, Annovis reported cash and cash equivalents of $18.7 million as of June 30, 2026, and a net loss of $14.8 million for the second quarter, reflecting increased R&D spending. The company will host a corporate update webinar on September 2, 2026.

Key Actions
100 Annovis Bio fully enrolled
80 Annovis Bio enrolled
70 Annovis Bio reported
40 Annovis Bio promoted Cheng Fang
Entities Involved
stock
Annovis Bio
Annovis Bio is the central entity, achieving full enrollment in its pivotal Phase 3 AD trial and advancing its pipeline. The company's financial position remains tight with $18.7 million cash, but the clinical progress could enhance its valuation if data are positive.
Importance 100.0 Sentiment 60.0
per
Maria Maccecchini
As President and CEO, Maria Maccecchini is the public face of the company's progress, highlighting the milestone of full enrollment and the company's readiness for regulatory submission. Her leadership is critical to the company's strategic direction.
Importance 70.0 Sentiment 50.0
per
Cheng Fang
Cheng Fang was promoted to Chief Scientific Officer, a move that strengthens the company's scientific leadership as it approaches key regulatory milestones. This promotion signals continuity and expertise in clinical execution.
Importance 40.0 Sentiment 40.0
per
Alexander Wang
Alexander Wang, as Director of Strategic Communications, is responsible for investor relations and communications, playing a supporting role in disseminating the company's updates and managing investor engagement.
Importance 10.0 Sentiment 30.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.